Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
- Sponsor
- Beijing Tiantan Hospital
- Study ID
- NCT05968053
- Status
- Recruiting
Conditions
- Brain Tumor
- Carotid Artery Stenosis
- Glioma
- Intracranial Aneurysm
- Intracranial Hemorrhages
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- biological samples analysis — DIAGNOSTIC_TESTbiological samples analysis
Study Details
Plastic particles are a ubiquitous pollutant in the living environment and food chain, so far, plenty of studies have reported the internal exposure of microplastics and nanoplastics in human tissues and enclosed body fluids. Neurosurgery is the only department that can open the skull. In addition to blood and cerebrospinal fluid, there are brain tissue and tumors in the presence of lesions. Whether any of these microplastics and nanoplastics are present remains a mystery. This prospective observational study will harvest biological samples of neurosurgery patients. The objective of this research is to be able to detect microplastics and nanoplastics on blood and operation samples of neurosurgery patients.
Key Dates
- First listed
- Aug 1, 2023
- Start date
- Sep 25, 2023
- Status verified
- Jan 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
microplastics [ Time Frame: baseline, intraoperative ]
Central Contacts
- Xiaolin Chen, MD13810624845
- Fa Lin, MD13681107240
Find similar trials
Related Studies
- Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)PHASE1/PHASE2 · Recruiting · Plus Therapeutics · Manhasset, New York